I suppose some will blame BTA mgmt for this.
Current BTA had nothing to do with Relenza licencing. In the industry 7%-10% is not a bad deal anywway for his type of thing.
We all know about the GSK/BTA court case. ABOBO/ peter crook keeps remionding us. Why rehash this again. WHY !!!
What good going forward does it bring. None.
- Forums
- ASX - By Stock
- BTA
- enterprise value $100m - lani superior tamiflu
enterprise value $100m - lani superior tamiflu, page-2
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)